Carla Abdelnour, PhD, Stanford University, Palo Alto, CA, discusses the challenges in designing clinical trials for dementia with Lewy bodies (DLB). Firstly, there is a lack of established, disease-specific genetic or biologic biomarkers for the diagnosis or prognosis of DLB. In terms of clinical trials, this makes it difficult to design subject criteria and enroll patients accordingly. Secondly, there are no validated outcome measures for DLB clinical trials and typically, outcome measures from Alzheimer’s disease or Parkinson’s disease trials are used instead. This interview took place at the Clinical Trials on Alzheimer’s Disease congress 2022 in San Francisco.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Carla Abdelnour reports the following disclosures: I’m a board member of the Lewy Body Dementia Association (LBDA), and I have received honoraria for presentations from F. Hoffmann-La Roche Ltd, Zambon, Nutricia and Schwabe Farma Ibérica S.A.U.